Daxor Corporation (NASDAQ:DXR) Sees Large Increase in Short Interest

Daxor Corporation (NASDAQ:DXR) saw a significant increase in short interest in December. As of December 31st, there was short interest totaling 8,248 shares, an increase of 159.8% from the December 15th total of 3,175 shares. Based on an average daily volume of 4,196 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.4% of the company’s shares are short sold. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 4,196 shares, the days-to-cover ratio is presently 2.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Daxor has an average rating of “Moderate Buy” and an average price target of $25.00.

Daxor Price Performance

Shares of NASDAQ:DXR opened at $13.88 on Wednesday. The firm has a 50 day moving average of $13.23 and a 200 day moving average of $11.98. Daxor has a 52 week low of $6.55 and a 52 week high of $14.76.

Institutional Investors Weigh In On Daxor

A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. acquired a new stake in shares of Daxor Corporation (NASDAQ:DXR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent reporting period. 1.34% of the stock is currently owned by institutional investors.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.